FAIR DATA SHARING & DATA CARING IN THE DIGITALIZED ERA: ASPIRATIONS, REALITIES & LEGAL CLASHES IN THE HEALTH & LIFE SCIENCES: Abstract of presentation at Stanford Law School
Research output: Contribution to conference › Conference abstract for conference › Research › peer-review
Standard
FAIR DATA SHARING & DATA CARING IN THE DIGITALIZED ERA: ASPIRATIONS, REALITIES & LEGAL CLASHES IN THE HEALTH & LIFE SCIENCES : Abstract of presentation at Stanford Law School. / Minssen, Timo.
2018. Abstract from BIOLAWLAPALOOZA 2018, Palo Alto, United States.Research output: Contribution to conference › Conference abstract for conference › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - ABST
T1 - FAIR DATA SHARING & DATA CARING IN THE DIGITALIZED ERA: ASPIRATIONS, REALITIES & LEGAL CLASHES IN THE HEALTH & LIFE SCIENCES
T2 - BIOLAWLAPALOOZA 2018
AU - Minssen, Timo
PY - 2018/3
Y1 - 2018/3
N2 - The huge prospects of Big Data, advanced machine learning and AI, as well as the shift to more “personalized”, “open” and “transparent” innovation models stress the importance of an effective governance, regulation and stimulation of shareable data-applications in the health & life sciences. Yet, cutting edge medical innovation requires more than freely available big data and machine-generated data. Pushing the boundaries of biomedical research also demands smart data and high quality data that are created and nourished through human intervention and considerable investments in an highly competitive environment. Intellectual Property Rights (IPRs) and related rights come into play when data producers protect their investment in such data. While the need of recalibrating IPRs to fully support “big and smart data” advances is being intensely debated, there seems to be much confusion about the availability of IPRs and their legal effects. This presentation provides a very brief overview on selected areas that demonstrate emerging tensions at the interface of Big Data, Standardization, IPRs and Competition/Antitrust Law.
AB - The huge prospects of Big Data, advanced machine learning and AI, as well as the shift to more “personalized”, “open” and “transparent” innovation models stress the importance of an effective governance, regulation and stimulation of shareable data-applications in the health & life sciences. Yet, cutting edge medical innovation requires more than freely available big data and machine-generated data. Pushing the boundaries of biomedical research also demands smart data and high quality data that are created and nourished through human intervention and considerable investments in an highly competitive environment. Intellectual Property Rights (IPRs) and related rights come into play when data producers protect their investment in such data. While the need of recalibrating IPRs to fully support “big and smart data” advances is being intensely debated, there seems to be much confusion about the availability of IPRs and their legal effects. This presentation provides a very brief overview on selected areas that demonstrate emerging tensions at the interface of Big Data, Standardization, IPRs and Competition/Antitrust Law.
M3 - Conference abstract for conference
Y2 - 22 March 2018 through 23 March 2018
ER -
ID: 200346525